Quick Answer
Onconetix, Inc. reported Total Revenue of $815.4 thousand for fiscal year 2025.
Onconetix, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $815.4K -67.7% |
$2.52M +4217.3% |
$58.5K | — | — | — |
| Net Income | -$14.03M +76.1% |
-$58.69M -56.9% |
-$37.41M -178.8% |
-$13.42M -292.7% |
-$3.42M | — |
| Diluted EPS | -$16.56 +99.1% |
-$1823.39 -1985.1% |
-$87.45 -7850.0% |
-$1.10 +12.7% |
-$1.26 | — |
| Total Assets | $24.93M -11.5% |
$28.18M -67.8% |
$87.52M +232.6% |
$26.31M +752.9% |
$3.08M | — |
| Cash and Equivalents | — | — | — | $25.75M +1235.4% |
$1.93M | — |
| Stockholders Equity | $15.76M +84.5% |
$8.54M +252.5% |
-$5.60M -125.0% |
$22.39M +1447.7% |
$1.45M -69.4% |
$4.73M |
| R&D Expense | — | $154.4K -92.1% |
$1.95M -52.8% |
$4.13M +211.7% |
$1.33M | — |
| Operating Income | -$17.86M +68.4% |
-$56.49M -56.8% |
-$36.03M -167.3% |
-$13.48M -294.5% |
-$3.42M | — |
| Gross Profit | $632.9K -40.0% |
$1.06M +193.6% |
-$1.13M | — | — | — |
| Shares Outstanding | 1.56M +1028.2% |
138,270 -75.2% |
558,099 -96.3% |
15.27M +377.0% |
3.20M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $303.7K | -25.4% | +185.1% |
| Revenue (ASC 606) | September 30, 2024 | $406.9K | — | -42.3% |
| Net Income | September 30, 2025 | -$8.78M | -129.5% | -270.2% |
| Diluted EPS | September 30, 2025 | -$6.25 | +97.5% | -31.3% |
| Total Assets | September 30, 2025 | $19.68M | -68.2% | +2.9% |
| Cash and Equivalents | September 30, 2022 | $29.14M | — | +31.0% |
| Stockholders Equity | September 30, 2025 | $3.37M | -90.1% | -42.9% |
| R&D Expense | March 31, 2025 | $24.5K | -50.1% | -77.6% |
| Operating Income | September 30, 2025 | -$2.07M | +21.8% | -6.9% |
| Gross Profit | September 30, 2025 | $268.9K | +155.1% | +281.4% |
| Shares Outstanding | September 30, 2025 | 1.56M | -81.2% | +54.7% |
- Onconetix, Inc. reported Total Revenue of $815.4 thousand for fiscal year 2025.
- Onconetix, Inc. showed a decrease of -67.7% in Total Revenue compared to the prior fiscal year.
- Onconetix, Inc. reported Net Income of -$14.03 million for fiscal year 2025.
- Onconetix, Inc. showed an increase of +76.1% in Net Income compared to the prior fiscal year.
- Onconetix, Inc. reported Diluted EPS of $16.56 per share (loss) for fiscal year 2025.
- Onconetix, Inc. showed an increase of +99.1% in Diluted EPS compared to the prior fiscal year.
- Onconetix, Inc. reported Total Assets of $24.93 million for fiscal year 2025.
- Onconetix, Inc. showed a decrease of -11.5% in Total Assets compared to the prior fiscal year.
- Onconetix, Inc. reported Cash and Equivalents of $25.75 million for fiscal year 2022.
- Onconetix, Inc. showed an increase of +1235.4% in Cash and Equivalents compared to the prior fiscal year.
- Onconetix, Inc. reported Stockholders Equity of $15.76 million for fiscal year 2025.
- Onconetix, Inc. showed an increase of +84.5% in Stockholders Equity compared to the prior fiscal year.
- Onconetix, Inc. reported R&D Expense of $154.4 thousand for fiscal year 2024.
- Onconetix, Inc. showed a decrease of -92.1% in R&D Expense compared to the prior fiscal year.
- Onconetix, Inc. reported Operating Income of -$17.86 million for fiscal year 2025.
- Onconetix, Inc. showed an increase of +68.4% in Operating Income compared to the prior fiscal year.
- Onconetix, Inc. reported Gross Profit of $632.9 thousand for fiscal year 2025.
- Onconetix, Inc. showed a decrease of -40.0% in Gross Profit compared to the prior fiscal year.
- Onconetix, Inc. reported Shares Outstanding of 1.56 million shares for fiscal year 2025.
- Onconetix, Inc. showed an increase of +1028.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: